We are live on ! Find out more
WST icon

West Pharmaceutical

250 hedge funds and large institutions have $4.71B invested in West Pharmaceutical in 2016 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 96 increasing their positions, 83 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

16% more capital invested

Capital invested by funds: $4.05B → $4.71B (+$663M)

16% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 83

12% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 26

1% more funds holding

Funds holding: 248250 (+2)

0.64% more ownership

Funds ownership: 93.49%94.13% (+0.64%)

Holders
250
Holders Change
+2
Holders Change %
+0.81%
% of All Funds
6.66%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.16%
New
29
Increased
96
Reduced
83
Closed
26
Calls
$1.28M
Puts
Net Calls
+$1.28M
Net Calls Change
-$1.15M
Name Holding Trade Value Shares
Change
Change in
Stake
PIM
201
Penobscot Investment Management
Massachusetts
$259K -$78.8K -1,310 -26%
WAM
202
World Asset Management
Michigan
$245K +$9.69K +161 +5%
PP
203
Prudential plc
United Kingdom
$243K
BCA
204
Bray Capital Advisors
Florida
$237K
MA
205
Montag & Associates
Georgia
$236K
SIM
206
Sonora Investment Management
Arizona
$223K
US Bancorp
207
US Bancorp
Minnesota
$206K -$25.7K -427 -13%
FAM
208
Fortaleza Asset Management
Illinois
$204K
LIA
209
LS Investment Advisors
Michigan
$200K +$13.5K +225 +8%
Fifth Third Bancorp
210
Fifth Third Bancorp
Ohio
$198K +$146K +2,424 +559%
First Manhattan
211
First Manhattan
New York
$194K
LTFS
212
Ladenburg Thalmann Financial Services
Florida
$175K -$1.32K -22 -0.9%
CIM
213
Contravisory Investment Management
Massachusetts
$147K -$34.2K -568 -21%
Zurich Cantonal Bank
214
Zurich Cantonal Bank
Switzerland
$139K
AIM
215
Assured Investment Management
New York
$120K +$104K +1,736 New
GWM
216
Geneos Wealth Management
Colorado
$105K +$90.2K +1,500 New
ST
217
Smithfield Trust
Pennsylvania
$83K
FHA
218
First Horizon Advisors
Tennessee
$80K +$8K +133 +13%
Pacer Advisors
219
Pacer Advisors
Pennsylvania
$79K +$68.7K +1,142 New
AssetMark Inc
220
AssetMark Inc
California
$69K +$1.44K +24 +2%
CK
221
Carnick & Kubik
Colorado
$69K +$60.2K +1,000 New
Barclays
222
Barclays
United Kingdom
$53K -$171K -2,838 -78%
RFC
223
Russell Frank Company
Washington
$42K
DADC
224
D.A. Davidson & Co
Montana
$40K -$111K -1,837 -76%
Geode Capital Management
225
Geode Capital Management
Massachusetts
$33.3K +$1.39M +23,029 +5%

WST Hedge Fund Activity: Q1 2016 in Review

250 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q1 2016, worth a combined $4.71B — up 16% from $4.05B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new WST positions and 26 closed out — a net gain of 3 holders — while 96 added to existing stakes and 83 trimmed.

The largest buyer was Select Equity Group, adding an estimated $54.2M. The largest seller was Kalmar Investments, cutting an estimated $29.4M.

  • 250 institutional investors held West Pharmaceutical (WST) as of Q1 2016, up from 248 in Q4 2015.
  • Funds reported $4.71B of West Pharmaceutical stock for Q1 2016, up 16% quarter-over-quarter.
  • 29 funds opened new West Pharmaceutical positions in Q1 2016 and 26 closed out, a net change of +3 holders.
  • The largest West Pharmaceutical buyer in Q1 2016 was Select Equity Group, an estimated $54.2M added.
  • The largest West Pharmaceutical seller in Q1 2016 was Kalmar Investments, an estimated $29.4M sold.

Based on aggregated 13F filings for Q1 2016.